If i didnt mistake that Norvatis had followed the stem cell tech long time ago, they even had product, so they know exactly the science especially the datas in Japan for years ,which leaded Lonza had to expend on the manufacturing . One more thing, the DSMB only RECOMMENDED, and both sides agreed to stop to get the data earlier to create a new trial base on these datas.
Again just my 2 cents reading
MSB Trading 2021 - paradigm shift, page-123
-
- There are more pages in this discussion • 10,088 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.02 |
Change
-0.053(4.91%) |
Mkt cap ! $1.221B | |||
| Open | High | Low | Value | Volume |
| $1.05 | $1.05 | $1.02 | $2.226M | 2.157M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 15 | 136706 | $1.02 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.02 | 81304 | 10 |
View Market Depth
| Last trade - 10.42am 30/07/2024 (20 minute delay) ? |
| MSB (ASX) Chart |